Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OLMA vs NUVB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NUVB Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)

NUVB Overall Winner 6-Pillar Tally: OLMA 1 – 4 NUVB (1 Tie) Matrix Metrics: OLMA 3 – 5 NUVB

As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Olema Pharmaceuticals, Inc. (OLMA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). OLMA carries a Unified Composite Score of 39.9/100 (SELL) at $7.02 (N/M Forward P/E, 0.0% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin).

  • Technical & Structure Timing Caution: OLMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.9); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OLMA vs NUVB
OLMA NASDAQ
Olema Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$7.02
-1.82% 1D
Market Cap $626.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.57β · 83% Vol
Unified Composite Score
39.9 / 100 SELL
Tech 38.0 Fund 50.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.9%), weak momentum, RSI 44
RSI-14: 43.9 · SMA20: $7.25 · SMA50: $7.84
NUVB NYSE Head-to-Head Winner
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87

6-Pillar Scorecard Institutional Category Breakdown (OLMA 1 – 4 NUVB)

Columns: Metric · OLMA · NUVB
1. Valuation Multiples NUVB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 7.4x
2. Growth & Scale NUVB
Revenue Growth (YoY) +0.0% +242.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $202M
Market Cap $626.4M $1.3B
3. Profitability & Quality OLMA
Gross Margin N/A 85.8%
Operating Margin 0.0% -61.2%
Net Profit Margin 0.0% -67.4%
Return on Equity (ROE) -69.8% -49.1%
4. Balance Sheet & Cash Flow NUVB
Cash Generation (TTM) -$178M -$108M
Cash Flow Margin N/A -53.6%
Net Cash / Leverage $44M Net Cash $146M Net Debt (1.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NUVB
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 287.4% (31st %ile) 65.2% (26th %ile)
Put/Call OI Skew 500.14x (Put-Skewed) 0.24x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OLMA (3) vs NUVB (5)
Institutional Metric OLMA NUVB Criterion Row Edge
Market Capitalization
Scale
$626.4M $1.3B Larger Scale NUVB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +242.6% Higher Growth NUVB
Operating Margin (TTM)
Profitability
0.0% -61.2% Higher Margin OLMA
Net Profit Margin
Profitability
0.0% -67.4% Higher Margin OLMA
Return on Equity (ROE)
Capital Efficiency
-69.8% -49.1% Higher ROE NUVB
52-Week Range Position
Momentum
3% ($6–$36) 2% ($4–$10) Stronger Trend OLMA
Beta / 30D Volatility
Risk Regime
1.57β · 83% Vol 1.52β · 55% Vol Lower Realized Risk NUVB
Unified Institutional Score
Composite Signal
39.9 / 100 (SELL) 61.0 / 100 (BUY) Higher Composite NUVB
Trailing 12M Revenue (USD)
Operating Scale
N/A $202M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 85.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$178M ($44M Net Cash) -$108M ($146M Net Debt (1.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OLMA +19.15 pp
OLMA: +0.0% · NUVB: -19.15%
3M Horizon OLMA +11.1 pp
OLMA: -32.69% · NUVB: -43.79%
6M Horizon NUVB +29.19 pp
OLMA: -48.68% · NUVB: -19.49%
1Y Horizon NUVB +17.02 pp
OLMA: -63.87% · NUVB: -46.85%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OLMA vs NUVB. Trailing 12-month operating profitability (OLMA 0.0% vs NUVB -61.2%) and valuation multiples (OLMA N/M vs NUVB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OLMA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.8% · N/M
NUVB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$202M
Gross Margin85.8%
Op. Margin-61.2%
ROE / Fwd P/E-49.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OLMA BREAKDOWN
98d in phase · OBV DISTRIBUTION
Current IV 287.4%
IV Percentile 31st %ile
Put/Call OI Skew 500.14x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact OLMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OLMA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $626.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OLMA vs NUVB Key Questions & Quantitative Answers

As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Olema Pharmaceuticals, Inc. (OLMA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). OLMA carries a Unified Composite Score of 39.9/100 (SELL) at $7.02 (N/M Forward P/E, 0.0% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin). Technical & Structure Timing Caution: OLMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.9); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: OLMA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NUVB at +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin). On trailing 12-month operating scale, OLMA generates N/A in USD-normalized revenue versus $202M for NUVB. In operating R&D and SG&A reinvestment, OLMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUVB.

NUVB screens cheaper on headline valuation multiples. OLMA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OLMA (-69.8% ROE) versus NUVB (-49.1% ROE) capital efficiency.

In options market volatility and institutional positioning, OLMA carries 287.4% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 500.14x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.57β · 83% Vol realized risk). By comparison, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.